Tralokinumab is a monoclonal antibody targeting interleukin-13, used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy. The DrugMonitor™ Anti-Tralokinumab Antibody (VS-1224-YC1235) is an anti-drug antibody (ADA) against Tralokinumab. This drug-based antibody is raised in mice immunized with the Tralokinumab. The anti-Tralokinumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Tralokinumab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Anti-Human IL13 Recombinant Antibody (Tralokinumab)Recombinant monoclonal antibody to IL13. Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.
Afuco™ Anti-IL13 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-218)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL13. It is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.
There are currently no Customer reviews or questions for VS-1224-YC1235. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.